



ASX ANNOUNCEMENT

Lumos secures initial development services contract with Aptatek

- *Lumos has secured development services contract with Aptatek for a point-of-care/at-home test for screening of phenylketonuria (PKU);*
- *Initial phase of the partnership expected to generate at least US\$0.5 million in revenue for the development of an assay and reader;*
- *Potential for additional development and ongoing instrument manufacturing activities subject to successful completion of the initial phase by the end of CY2022.*

Melbourne, VIC. (17 June 2022) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, today announces that it has secured a development contract with New Jersey-based Aptatek Biosciences, Inc. to develop a product to assist with screening for phenylketonuria (PKU).

PKU is a rare inherited disorder which causes an amino acid called phenylalanine to build up in the body and affects approximately 1 in 12,000 newborns. Left untreated, this build-up can result in intellectual disabilities, seizures, behavioural problems and mental disorders. The Aptatek product, developed under contract with Lumos, aims to provide a point-of-care/at-home screening test to allow PKU patients to directly measure their phenylalanine levels in real-time. Such a test has the potential to allow more rapid identification and effective on-going management of the disorder. The product has already been given breakthrough status from the FDA which is expected to accelerate its approval timeframe.

The initial phase of this partnership is expected to generate at least US\$0.5 million in revenue for Lumos with further potential revenue from additional development activities and ongoing instrument manufacturing conducted in subsequent phases of the partnership. Aptatek is aiming to commence further studies and activities using the test developed by Lumos in Q1 CY2023 with US commercial launch expected later in CY2023. Subject to regulatory approvals and execution of a commercial contract manufacturing agreement, Aptatek intends to engage Lumos as the instrument manufacturing partner for the product.

“Aptatek is focused on providing transformational tools for improving the management of chronic diseases,” said Mike Boyce Jacino, CEO of Aptatek Biosciences Inc. “We are delighted to have Lumos as our partner in this ambitious effort.”

“We are very pleased that Aptatek selected Lumos as its development partner following a competitive bidding process” said Sam Lanyon, Lumos’ Interim CEO. “Aptatek’s objective of replacing a centralised PKU diagnostic test with a POC test that can be used in the home highlights the broad shift towards decentralised testing that has the potential to deliver better outcomes for patients. We are excited to be Aptatek’s development partner for such an important product and look forward to continuing this relationship as the product moves into manufacturing and commercial launch.”

#

About Aptatek

Aptatek is a mobile health company developing innovative systems combining novel sensing technology and innovative digital health tools to enable detection and monitoring of small molecule targets on a portable platform. The privately held company is commercializing technology developed by Columbia scientists and licensed from Columbia University by Aptatek and is based in Princeton, New Jersey

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598